In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.50. The company’s shares opened today at ...

North Carolina is a leading place for biotech, and a big part of that success comes from GlaxoSmithKline (GSK). This global ...

GlaxoSmithKline, the London-based pharmaceutical giant with a substantial presence in Montgomery County and Philadelphia, ...

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on October 9. Graham ...

Aditya Birla SL ELSS Tax Saver Fund (IDCW) 262.21 9,53,316 1.53 Aditya Birla SL ELSS Tax Saver Fund (G) 262.21 9,53,316 1.53 Aditya Birla SL ELSS Tax Saver Fund ...

There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of ...

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

News for GlaxoSmithKline Consumer Healthcare Ltd. HUL Faces Rs 963 Cr Income Tax Demand: Appeal Planned Hindustan Unilever (HUL) received a Rs 963 crore Income Tax demand for non-deduction of TDS on ...

Despite strong cash flow and organic growth in most of its key brands, high leverage and mixed valuation ratios lead to a ...

An analysis of the FINEARTS-HF trial, which showed finerenone's benefits in heart failure outcomes, shows no significant ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...